UVA Health researchers analyzed real-world outcomes from 972 patients treated with histotripsy, a noninvasive liver tumor treatment using focused sound waves. While procedural complications and toxicity were low, 11% of patients died within 30 days, prompting questions about patient selection and timing. Researchers say identifying who truly benefits from this promising technology remains critical.
UVA researchers have discovered that calcium channels in glioblastoma tumor cells and surrounding neurons drive tumor growth. Blocking these channels with the FDA-approved drug mibefradil slowed tumor formation in mice and could sensitize cancer cells to radiation and chemotherapy, offering a promising new treatment strategy for this deadly brain cancer.
Yaohua Yang, PhD, of UVA’s Department of Genome Sciences has been awarded a five-year, $3.5 million NCI R37 MERIT grant to study RNA modifications called m6A marks and their role in lung cancer risk.
UVA researchers discovered how an unhealthy gut may help breast cancer spread – and how an existing drug could potentially stop it.
New research from the UVA Department of Surgery’s Tsung Research Group, published in JAMA Network Open and selected as an Editor’s Pick, provides a national evaluation of real-world use of histotripsy for liver tumors.
UVA Health researchers have found that gliomas, the most common primary brain tumors in adults, may be more receptive to focused ultrasound drug delivery than normal brain tissue.
GET THE STORIES BEHIND THE RESEARCH
Receive updates about the discoveries, researchers, and ideas shaping our world — straight from UVA.
UVA’s Center for Systems Analysis of Stress-adapted Cancer Organelles (SASCO) recently held its annual symposium, hosting a pair of leading figures in breast cancer research and sharing findings including identification […]
UVA scientists have developed a promising new approach to targeting glioblastoma, the most common and deadliest brain cancer, that could overcome limitations of existing drugs.
New research from UVA’s Melanie Rutkowski, PhD, and colleagues helps explain how the gut microbiome – the collection of microorganisms that live in and on our intestines – plays a role in the spread of hormone receptor-positive (HR+) breast cancer.
A University of Virginia School of Engineering and Applied Science faculty researcher earned a major new federal grant to develop emerging tools to work with some of the rarest circulating cells in the human body, a step toward better treatments for diseases such as cancer and infection.
UVA researchers Mark Conaway, PhD, and Gina Petroni, PhD, have received a four-year, $1.95 million NIH R01 grant to develop statistical methods for analyzing ELISpot assay data in early phase cancer trials. The research aims to help identify effective immunotherapies faster, discard ineffective ones earlier, and predict long-term clinical benefit from short-term immune response data.
The Leventals have identified a key mechanism by which T cells recognize cancerous cells. T cells detect and kill infected cells. This process, the Levental Lab discovered, is facilitated by the interaction between the cell membrane and protein condensates — cellular structures that organize cytoplasm.